Seek Returns logo

ABT vs. SMMT: A Head-to-Head Stock Comparison

Updated

Here’s a clear look at ABT and SMMT, comparing key factors like performance, valuation metrics, dividends, and financial strength. It’s built for investors or anyone curious to see how these two stocks match up.

Company Overview

ABT dwarfs SMMT in market cap, clocking in at 231.49 billion USD—about 12.35 times the 18.74 billion USD of its counterpart.

SMMT dances to a riskier tune, sporting a beta of -0.95, while ABT keeps it calmer at 0.74.

SymbolABTSMMT
Company NameAbbott LaboratoriesSummit Therapeutics Inc.
CountryUSUS
SectorHealthcareHealthcare
IndustryMedical - DevicesBiotechnology
CEOMr. Robert B. FordMr. Robert W. Duggan
Price133.05 USD25.41 USD
Market Cap231.49 billion USD18.74 billion USD
Beta0.743-0.948
ExchangeNYSENASDAQ
IPO DateMarch 17, 1980March 5, 2015
ADRNoNo

Performance Comparison

This chart compares the performance of ABT and SMMT over the past year by tracking the growth of an initial $10,000 investment in each (starting one year ago).

Hover over the lines to see the investment’s value and total return (%) at specific dates.

Data is adjusted for dividends and splits.

Valuation Metrics Comparison

The section examines key financial ratios to assess the valuation of ABT and SMMT based on earnings, cash flow, sales, and book value. Pay attention to the following notable points where extreme values stand out.

  • SMMT shows a negative P/E of -77.90, highlighting a year of losses with no net profit generated. Meanwhile, ABT at 17.22 has sustained positive earnings, offering a more stable earnings foundation.
  • SMMT has a negative Price-to-Free Cash Flow of -108.01, indicating it’s spent more cash than it’s brought in over the past year—a cash flow shortfall that raises questions about its operational sustainability. Meanwhile, ABT at 34.77 maintains a positive cash position.
SymbolABTSMMT
Price-to-Earnings Ratio (P/E, TTM)17.22-77.90
Forward PEG Ratio (TTM)1.738.05
Price-to-Sales Ratio (P/S, TTM)5.470.00
Price-to-Book Ratio (P/B, TTM)2.4854.47
Price-to-Free Cash Flow Ratio (P/FCF, TTM)34.77-108.01
EV-to-EBITDA (TTM)22.97-107.59
EV-to-Sales (TTM)5.630.00
EV-to-Free Cash Flow (TTM)35.78-106.83

Dividend Comparison

ABT’s 1.71% yield offers steady income while retaining earnings for growth, unlike SMMT, which pays none, reinvesting fully—likely in expansion or R&D—for investors eyeing future gains. This pits ABT’s balanced approach against SMMT’s long-term focus.

SymbolABTSMMT
Dividend Yield (TTM)1.71%0.00%

Financial Strength Metrics Comparison

This section dives into the financial resilience of ABT and SMMT, spotlighting key metrics like liquidity, leverage, and debt coverage. Check out the standout observations below where notable differences or extremes pop up.

  • SMMT’s -30.27 sits under 1.5, where earnings hug interest costs too closely—a squeeze if income dips. Meanwhile, ABT at 15.39 has room to breathe.
SymbolABTSMMT
Current Ratio (TTM)1.7810.63
Quick Ratio (TTM)1.2710.63
Debt-to-Equity Ratio (TTM)0.140.02
Debt-to-Assets Ratio (TTM)0.160.02
Interest Coverage Ratio (TTM)15.39-30.27